The product, which is a next generation basal insulin, is a once-daily long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.
"The launch of Toujeo reaffirms our strong commitment of expanding Sanofi's portfolio and to drive better diabetes management in India," Sanofi India Managing Director N Rajaram said in a statement.
Toujeo was first approved in 2015 in the United States and since then, it has been approved in over 65 countries.
It is a prescription drug and is available in the newly designed SoloSTAR pen.
It works by slowly releasing small amounts of insulin to provide continuous glucose-lowering activity that lasts beyond 24 hours, it added.
Sanofi India shares were trading up 2.27 per cent at Rs 4,828.75 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)